Hulse Gary K
Addiction Medicine, School of Psychiatry & Clinical Neurosciences (M521), The University of Western Australia, Crawley, WA, Australia.
Br J Clin Pharmacol. 2013 Nov;76(5):632-41. doi: 10.1111/j.1365-2125.2012.04452.x.
Despite being a relatively effective and safe treatment, the clinical management of alcohol abuse/dependence by oral naltrexone can be compromised due to the patient's non-compliance with daily use of this medication. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone preparations can overcome this issue and deliver improved clinical outcomes. However, at the same time, research findings from diverse areas of pharmacogenetics, neurobiology and behavioural psychology have also been converging to identify variables including genetic markers, patient psychosocial characteristics and drug use history differences, or clusters of these variables that play a major role in mediating the response of alcohol abuse/dependent persons to treatment by naltrexone. While this article does not attempt to review all available data pertaining to an individual alcohol dependent patient's response to treatment by naltrexone, it does identify relevant research areas and highlights the importance of data arising from them. The characterization of clinical markers, to identify those patients who are most likely to benefit from naltrexone and to tailor a more individual naltrexone treatment, will ultimately provide significant benefit to both patients and clinicians by optimizing treatment outcome.
尽管口服纳曲酮是一种相对有效且安全的治疗方法,但由于患者不遵守每日用药规定,酒精滥用/依赖的临床管理可能会受到影响。在过去十年中,越来越多的研究表明,使用缓释长效纳曲酮制剂可以克服这个问题,并带来更好的临床效果。然而,与此同时,来自药物遗传学、神经生物学和行为心理学等不同领域的研究结果也趋于一致,以确定包括基因标记、患者心理社会特征和药物使用史差异等变量,或这些变量的组合,它们在介导酒精滥用/依赖者对纳曲酮治疗的反应中起主要作用。虽然本文不试图回顾与个体酒精依赖患者对纳曲酮治疗反应相关的所有现有数据,但它确实确定了相关研究领域,并强调了这些领域产生的数据的重要性。临床标志物的特征化,以识别那些最有可能从纳曲酮中获益的患者,并定制更个性化的纳曲酮治疗,最终将通过优化治疗结果为患者和临床医生带来显著益处。